Viridian Therapeutics, Inc.
VRDN
$23.02
-$0.15-0.65%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 278.67% | 95.83% | 83.33% | 81,958.14% | 4.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 278.67% | 95.83% | 83.33% | 81,958.14% | 4.17% |
| Cost of Revenue | -17.37% | 1.04% | 28.83% | 24.73% | 54.16% |
| Gross Profit | 17.63% | -0.95% | -28.78% | 77.28% | -54.22% |
| SG&A Expenses | 171.94% | 126.15% | 116.07% | 68.81% | 25.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.45% | 23.82% | 44.36% | 32.33% | 47.86% |
| Operating Income | -18.27% | -23.76% | -44.33% | 52.07% | -47.90% |
| Income Before Tax | -26.19% | -20.70% | -50.96% | 54.88% | -54.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.19% | -20.70% | -50.96% | 54.88% | -54.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.19% | -20.70% | -50.96% | 54.88% | -54.99% |
| EBIT | -18.27% | -23.76% | -44.33% | 52.07% | -47.90% |
| EBITDA | -18.28% | -23.79% | -44.40% | 52.13% | -48.04% |
| EPS Basic | -4.09% | -3.61% | -32.98% | 61.07% | -29.72% |
| Normalized Basic EPS | 4.56% | 3.95% | -31.78% | 63.36% | -21.30% |
| EPS Diluted | -4.09% | -3.61% | -32.98% | 61.07% | -29.72% |
| Normalized Diluted EPS | 4.56% | 3.95% | -31.78% | 63.36% | -21.30% |
| Average Basic Shares Outstanding | 32.22% | 25.65% | 17.89% | 23.13% | 27.78% |
| Average Diluted Shares Outstanding | 32.22% | 25.65% | 17.89% | 23.13% | 27.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |